$IPCALAB

Fundamental: Revenue +6.3% YoY | PAT +380% YoY | TTM PAT CAGR +572% | P/E 34.25x vs sector 54.4x (37% discount) | Upside 26.2% | Operating Margin 21.4% (+1,115 bps) | ROCE 18.6% | Rank #2/29 peers | Rating 8.53 Technical: Classic HH-HL uptrend since late last year — 5/9/13 EMAs fanning out above 200 EMA (₹1,490) in strong bullish alignment | Consolidating below ₹1,680 resistance | RSI 58 — bullish, ample room before overbought | MACD hovering in positive territory Moat: Integrated pharma player with a strong domestic branded generics franchise and a recovering US business — 1,115 bps operating margin expansion signals a structural profitability reset as API integration and export mix improvement compound simultaneously. View: Ranked #2 in its segment with a 37% P/E discount to pharma midcap peers, massive margin recovery underway, and a textbook uptrend structure approaching a key breakout zone — one of the cleanest risk-reward setups in mid-cap pharma right now.